Kyverna Therapeutics, Inc. — Form 8-K
Filed July 27, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 58/100
What the filing says
Kyverna Therapeutics and ElevateBio announced a new commercial manufacturing and supply agreement for miv-cel (mivocabtagene autoleucel), Kyverna's autologous CD19-directed CAR T-cell therapy. The agreement provides flexible and scalable U.S. commercial and global clinical supply to support potential launches in stiff person syndrome (SPS) and generalized myasthenia gravis (gMG), building on a three-year clinical-stage partnership with 98%+ manufacturing success rate. No financial terms were disclosed; Kyverna remains on track for Q4 2026 rolling BLA submission for miv-cel in SPS.
Why this rating
Secures critical manufacturing capacity for late-stage CAR-T candidate approaching BLA; reduces regulatory/supply risk at pivotal moment, but no new clinical data or near-term revenue impact disclosed.
See more from July 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.